kidney transplant
Conditions
Interventions
Valgancilovir group:None
Letermovir group:None
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients received letermovir or valganciclovir prophylaxis after kidney transplantation within 10 days and a duration of at least 90 days. 2.Age >= 18 years, male or female; 3.CMV IgG test positive and CMV DNA test negative.
Exclusion criteria
Exclusion criteria: 1.Patients with CMV infection or CMV history within 30 days before enrollment; 2.Patients with allergy to letermovir/ valganciclovir or related dosage form components; 3.Patients with severe liver damage, Child-Pugh score C; 4.Pregnant or lactating women; 5.Patients who use anti-CMV drugs within 7 days before enrollment; 6.Do not sign the informed consent; 7.Any other factors that may interfere with the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of clinically significant CMV infection; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of CMV disease (CMV syndrome and/or tissue-invasive CMV;Time to onset of adjudicated CMV disease;Incidence of acute graft rejection, graft loss and other infections.; | — |
Countries
China
Contacts
Public ContactDing Xiaoming
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed